Healthcare & Pharmaceuticals

New pain relief for cats with osteoarthritis gets U.S. approval

1 minute read

A woman carries her pet cat inside of a backpack as she walks along a street in downtown Washington, U.S., March 11, 2020. REUTERS/Carlos Barria

Register now for FREE unlimited access to Reuters.com

Jan 13 (Reuters) - The U.S. health regulator on Thursday approved Zoetis Inc's (ZTS.N) once-a-month injection to treat pain in cats with osteoarthritis, a common but difficult-to-diagnose condition that affects the joints in older cats.

Osteoarthritis breaks down the protective cartilage that cushions the joints, leading to increased friction that causes pain and decreased movement.

The drug, Solensia, with the active ingredient frunevetmab, is the first veterinary monoclonal antibody approved by the U.S. Food and Drug Administration.

Register now for FREE unlimited access to Reuters.com

Monoclonal antibodies are manufactured copies of antibodies created by the body to fight an infection.

Solensia was approved based on two effectiveness studies which used assessment of the cats by veterinarians and the scores from owners for the pets' movements before and after treatment.

The most common side-effects seen in cats from treatment with Solensia included vomiting, diarrhea, injection site pain and itchy skin.

Register now for FREE unlimited access to Reuters.com
Reporting by Leroy Leo; Editing by Devika Syamnath

Our Standards: The Thomson Reuters Trust Principles.

More from Reuters